Founded in Oberlin, United States, Synapse Biomedical is dedicated to advancing neurostimulation technology to aid individuals with spinal cord injuries. The company's core mission is to improve the quality of life for patients by reducing their dependence on mechanical ventilators. Synapse Biomedical's flagship product, the NeuRx Diaphragm Pacing System (DPS)®, is an FDA-approved, minimally invasive surgical procedure that conditions the diaphragm muscle, offering a significant breakthrough for spinal cord injury patients.
Notable affiliates and investors include prominent figures in the medical and biotech industries. Synapse Biomedical has successfully treated over 2000 patients with its NeuRx DPS®, which is eligible for coverage under Medicare, Medicaid, and private insurance. The company's innovative approach has had a substantial impact on patient care, providing a viable alternative to long-term mechanical ventilation and improving overall patient outcomes.
